Anybody wi_老虎社区_美港股上老虎

2021-10-13

Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up

Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":822814116,"tweetId":"822814116","gmtCreate":1634113464046,"gmtModify":1634113464134,"author":{"id":3576575729067569,"authorId":3576575729067569,"authorIdStr":"3576575729067569","name":"Ares_M","avatar":"https://static.tigerbbs.com/491b8c393aef71494a2e01a221f50bbc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up</p></body></html>","htmlText":"<html><head></head><body><p>Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up</p></body></html>","text":"Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/822814116","repostId":1113160181,"repostType":2,"repost":{"id":"1113160181","pubTimestamp":1634084984,"share":"https://www.laohu8.com/m/news/1113160181?lang=&edition=full","pubTime":"2021-10-13 08:29","market":"us","language":"en","title":"Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=1113160181","media":"Bloomberg","summary":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experiment","content":"<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p>\n<p>Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p>\n<p>Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p>\n<p>In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p>\n<p>The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 08:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"source_url":"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113160181","content_text":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.\nFunds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.\nCrispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.\nIn the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.\nThe ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":634,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GENE","AONE.U"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":115,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/822814116"}